Korean COVID-19 Contenders Still Racing Toward Finish Line
Oral Niclosamide Moves To Pivotal Stage
Hyundai Bioscience’s niclosamide-based oral antiviral moves into Phase II, joining other Korean COVID-19 treatment candidates in the pivotal trial stages, while SK Bioscience’s Phase III recombinant protein vaccine gears up for global market entry.
